---
title: CDMO Daily News — September 16, 2026
slug: daily-news-2026-09-16-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 16 CDMO daily: Argonaut Divests LSDx Unit to 1315 Capital, Reinvests in Fill-Finish Capacity; Interlabor's Dual-Path Troubleshooting Framework Cuts…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-16-cdmo
published_at: 2026-09-16T00:02:00.904Z
last_updated: 2026-09-16T00:04:29.292Z
---

### Argonaut Divests LSDx Unit to [1315 Capital](/companies/expericservices), Reinvests in Fill-Finish Capacity
- [Argonaut Manufacturing Services](/companies/argonautms) completed the sale of its Life Sciences and Diagnostics division to private equity firm [1315 Capital](/companies/expericservices); the unit will operate independently as [Aluris Sciences](/companies/aluris-sciences).
- Argonaut will reinvest sale proceeds into expanding aseptic fill-finish capacity and services for high-value injectable biologics at its Carlsbad, California facilities.
- No drug product programs, regulatory filings, or assets transferred; existing customer timelines, quality commitments, and contractual obligations remain unchanged.

**Operational Impact**

Argonaut's reinvestment of divestiture proceeds into aseptic fill-finish capacity at Carlsbad may increase available slots for biologics clients seeking dedicated or dedicated-equivalent manufacturing, though no timeline or capacity metrics were disclosed.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/argonaut-manufacturing-services-completes-sale-of-lsdx-division)*

---

### Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days
- [Interlabor Belp AG](/companies/interlabor-belp-ag) demonstrated a structured five-step troubleshooting workflow that runs parallel hypotheses simultaneously, eliminating sequential dead ends and compressing investigation timelines.
- Two case studies—benzene contamination in finished product and unknown residue in production pipe—showed root causes identified in 1–4 days using dedicated analytical instruments and on-site sampling.
- The model relies on flat hierarchies, fast internal approvals, and specialized equipment (IR microscope, GC-MS, SEM-EDX) reserved solely for troubleshooting rather than shared manufacturing schedules.

**Operational Impact**

CDMO customers relying on Interlabor for rapid contamination and residue investigation can expect root-cause identification within 1–4 days, enabling faster production restart and reduced compliance risk exposure.

*Source: [PharmaSource RSS](https://pharmasource.global/content/podcast/how-to-identify-a-root-cause-without-delay-interlabors-troubleshooting-framework)*

## References

1. [PharmaSource RSS — Argonaut Divests LSDx Unit to 1315 Capital, Reinvests in Fill-Finish Capacity](https://pharmasource.global/content/news/cdmo-news/argonaut-manufacturing-services-completes-sale-of-lsdx-division)
2. [PharmaSource RSS — Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days](https://pharmasource.global/content/podcast/how-to-identify-a-root-cause-without-delay-interlabors-troubleshooting-framework)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-16-cdmo